RIP2 kinase inhibitor 2 is a novel prodrug of a quinazolylamine that inhibits RIP2 kinase; it is used as a receptor-interacting protein-2 (RIP2) kinase inhibitor involved in innate immune signaling, potentially modulating NF-κB and mitogen-activated protein kinase pathways by disrupting RIP2-mediated scaffolding of kinases such as TAK1 and IKKα/β/γ.